跳转至内容
Merck

Y0000719

紫杉醇

European Pharmacopoeia (EP) Reference Standard

别名:

Paclitaxel

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C47H51NO14
CAS号:
分子量:
853.91
Beilstein:
1420457
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

paclitaxel

製造商/商標名

EDQM

mp

213 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7

InChI

1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

InChI 密鑰

RCINICONZNJXQF-MZXODVADSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Paclitaxel semi-synthetic for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

紫杉醇是一种有效的抗肿瘤和抗有丝分裂的紫杉烷类药物,可与 β-微管蛋白的N端结合,并使微管稳定,使细胞周期停滞在G2/M期。微管损伤通过依赖 JNK 的途径诱导细胞凋亡,随后通过不依赖 JNK 的途径诱导细胞凋亡,这可能与蛋白激酶 A(PKA)或 Raf-1 激酶的激活,进而导致 Bcl-2 磷酸化有关。通过 CYP2CB 的主要代谢物是 6α-羟基紫杉醇(6α-OHP)。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

注意

紫杉醇可在甲醇中进行酯交换反应,并在水溶液中发生水解。

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Muta. 2 - Repr. 1B - STOT RE 1

標靶器官

Central nervous system,Bone marrow,Cardio-vascular system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 2

1 of 2

Taroh Satoh et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(19), 2039-2049 (2014-05-29)
In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) -positive tumors. The role of anti-HER2 agents, including lapatinib, in this setting and population is unclear.
Miguel A Ojeda-Lopez et al.
Nature materials, 13(2), 195-203 (2014-01-21)
Bundles of taxol-stabilized microtubules (MTs)--hollow tubules comprised of assembled αβ-tubulin heterodimers--spontaneously assemble above a critical concentration of tetravalent spermine and are stable over long times at room temperature. Here we report that at concentrations of spermine several-fold higher the MT
Yoo-Joung Ko et al.
The Lancet. Oncology, 14(8), 769-776 (2013-05-28)
No standard treatment exists for patients with platinum-refractory urothelial cancer. Taxanes and vinflunine are commonly used, but response is less than 20% with no survival benefit. In this phase 2 study, we assessed efficacy and tolerability of nanoparticle albumin-bound (nab)
M Onrubia et al.
Current medicinal chemistry, 20(7), 880-891 (2012-12-06)
Taxol (paclitaxel) and its derivatives are microtubule-stabilizing drugs widely used in the treatment of several types of cancer, including mammary, prostate, ovarian and non-small-cell lung carcinoma, as well as AIDS-associated Kaposi's sarcoma and other types of tumor. Taxanes stabilize microtubules
Stěpán Koudelka et al.
Journal of controlled release : official journal of the Controlled Release Society, 163(3), 322-334 (2012-09-20)
Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门